Notably, the therapeutic efficacy of brontictuzumab against Notch1 was also significantly enhanced in combination with dexamethasone in T-ALL xenografts (129), implying that the effects are not dependent on pan-Notch inhibition or the pharmacodynamics of the GSI but rather result from synergy between the Notch1 inhibition and the increased glucocorticoid receptor activity. Here, NOTCH1 is linked to acute lymphoblastic leukemia.